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Fever occurs commonly in hospitalized patients. It is estimated
that nosocomial fevers occur in approximately one-third of all
medical patients at some time during their hospital stay [1]. In
patients admitted to the intensive care unit (ICU) with severe
sepsis, the incidence of fever is more than 90% [2]. As there
is variation in the incidence of reported fevers, the etiology of
fever in critically ill patients is similarly diverse—both infectious
and noninfectious etiologies are common [1,3,4].
The definition of fever is arbitrary. The mean body tempera-
ture (oral) in healthy individuals is approximately 36.8°C
(98.2°F), with a range of 35.6°C (96°F) to 38.2°C (100.8°F)
and a slight diurnal variation [5]. The Society of Critical Care
Medicine and the Infectious Disease Society of America, in a
recent consensus statement, suggested that a temperature of
above 38.3°C (101°F) should be considered a fever and
should prompt a clinical assessment [4].
Physician and staff response to fever varies institutionally.
Besides evaluating the patient and initiating a workup
based on the clinical evaluation, it is common for the
patient to receive either pharmacologic or mechanical
antipyretic therapy. However, there is little evidence that
would support such routine practice. The traditional view,
at least in pediatrics, is that an exuberant febrile response
is inherently dangerous and can, in the worse case, lead to
seizures and brain damage [6]. Adult nonhealthcare
workers (i.e. patient family members) also have significant
misconceptions regarding the perceived detrimental
effects of fever [7]. In this complicated psychosocial
setting, it is easy for the physician to merely treat the fever.
However, there are costs associated with such therapies. It
is estimated that when either paracetamol, icepacks or
cooling blankets are used, it can cost one 18-bed ICU
between $10,000 and $29,000 per year [8]. Pharmacolog-
ical means to reduce fever cause renal and hepatic dys-
function in patients who are volume depleted or who have
underlying kidney or liver disease [9]. Additionally, there is
evidence, at least in animal models, that fever is a benefi-
cial host response to infection [10–12].
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Abstract
Fever is a common response to sepsis in critically ill patients. Fever occurs when either exogenous or
endogenous pyrogens affect the synthesis of prostaglandin E2 in the pre-optic nucleus. Prostaglandin
E2 slows the rate of firing of warm sensitive neurons and results in increased body temperature. The
febrile response is well preserved across the animal kingdom, and experimental evidence suggests it
may be a beneficial response to infection. Fever, however, is commonly treated in critically ill patients,
usually with antipyretics, without good data to support such a practice. Fever induces the production
of heat shock proteins (HSPs), a class of proteins critical for cellular survival during stress. HSPs act
as molecular chaperones, and new data suggest they may also have an anti-inflammatory role. HSPs
and the heat shock response appear to inhibit the activation of NF-κβ, thus decreasing the levels of
proinflammatory cytokines. The anti-inflammatory effects of HSPs, coupled with improved survival of
animal models with fever and infection, call into question the routine practice of treating fever in
critically ill patients.
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The goal of the present review is to question, by critically
evaluating the literature, the practice of routinely treating fever
in the ICU patient. The pathophysiology of fever will be
reviewed, the animal and human data that have evaluated the
role and the potential beneficial effects of fever in disease
states will be examined, and the hemodynamic and metabolic
costs of fever will be summarized.
The physiology of fever
Fever is extremely well preserved throughout evolution. It has
been found in numerous phyla and is estimated to be more
than four million years old [13]. Fever is seen in mammals,
reptiles, amphibians, and fish as well as in some inverte-
brates. Not only is it found in endothermic (warm-blooded)
animals, it is also seen in ectothermic (cold-blooded) animals
[11]. In response to infection, lizards will elevate their body
temperature by selecting a warmer microclimate [14]. The
febrile response, defined by Plaisance and Mackowiak, is a
“complex physiologic reaction to disease involving a cytokine
mediated rise in core temperature, generation of acute-phase
reactants, and activation of numerous physiologic endocrino-
logic and immunologic systems” [15].
Exogenous stimuli, such as endotoxin, staphylococcal erytho-
toxin and viruses, induce white blood cells to produce
endogenous pyrogens. The most potent of these endo-
genous pyrogens are IL-1 and tumor necrosis factor alpha
(TNF-α) [16]. Other endogenous pyrogens that are integral in
the febrile response include IL-6 and the interferons [17].
These endogenous pyrogens act on the central nervous
system at the level of the organum vasculosum of the laminae
terminalis (OVLT). The OVLT is surrounded by the medial and
lateral portions of the pre-optic nucleus, the anterior hypo-
thalamus and the septum pallusolum [18].
The exact mechanism of how circulating cytokines in the
systemic circulation effect neural tissue remains unclear. It
has been hypothesized that a leak in the blood–brain barrier
at the level of the OVLT allows the central nervous system to
sense the presence of endogenous pyrogens. Additional pro-
posed mechanisms include active transport of cytokines into
the OVLT or activation of cytokine receptors in endothelial
cells of the neural vasculature, which than transduce signals
to the brain [19].
The OVLT synthesizes prostaglandin, especially prosta-
glandin E2, in response to endogenous pyrogens. Prosta-
glandin E2 acts directly on the cells of the pre-optic nucleus
to reduce the rate of firing of warm sensitive neurons, and it is
one of the downstream products of the arachidonic acid
pathway [20,21]. There is ample evidence that cyclooxyge-
nase-2 (COX-2) in neural vasculature is important in the for-
mation of fever. Induction of the febrile response by
lipopolysaccharide, TNF-α, and IL-1β resulted in increased
COX-2 mRNA in the cerebral vasculature of numerous exper-
imental models of fever [22]. In a murine model COX-2
knockout mice were unable to mount a febrile response to
endotoxin, and in humans COX-2 selective inhibitors were
shown to reduce fever [23,24]. In fact, over 30 years ago, the
NSAIDS were shown to inhibit the action of COX-2 [25].
Shortly afterwards, a similar mechanism was discovered for
acetaminophen, but this effect was only found in neural COX-
2 enzymes; thus explaining why acetaminophen is a strong
anti-pyretic but devoid of anti-inflammatory effects [26].
Fever and clinical outcomes
Although the febrile response has existed for millions of years,
controlled studies evaluating the benefits of fever do not exist.
Most of the studies in humans evaluating clinical outcomes,
fever and infection have been case–control series. For
example, in the pre-antibiotic era, artificial fever was used,
with limited success and without controlled trials, to treat
neurosyphilis [27,28]. Evaluation of fever in animal models is
confounded by the fact that stressed animals often increase
their body temperature several degrees with handling and is
confounded by questions about the appropriate pyrogenic
stimulus in a particular species [11]. It has been postulated
that a behavior so widely preserved, yet metabolically expen-
sive, must convey some net benefit to the host or it would not
have been retained during evolution [11].
In vitro and animal data evaluating the effect of temperature
on survival during infection suggest that fever may be benefi-
cial to the host. Increased survival with fever has been
demonstrated in animal studies [29,30]. In fact, the majority
of studies (14 out of 21 studies) evaluated in one review
demonstrated a deleterious effect of lowering body tempera-
ture [11]. Additionally, increasing temperature has effects on
the minimum inhibitory concentration of antibiotics to bacte-
ria. As the experimental temperature increased past 38.5°C,
the authors of one study found reductions in the minimum
inhibitory concentrations, representing a progressive increase
in the antimicrobial activity of antibiotics [31].
While in vitro data and animal data seems to suggest that
treatment of fever does not favorably impact morbidity and
mortality, human studies in this area are lacking. In a study
with 218 patients who had gram-negative bacteremia, fever
correlated positively with survival [32]. However, this data is
confounded by the fact that the majority of afebrile septic
patients who died did not receive appropriate antibiotic
therapy. Additionally, another retrospective case series
showed that failure to mount a febrile response within the first
24 hours was associated with increased mortality [33]. When
patient comfort was evaluated as a primary outcome variable,
there was no difference in the comfort level of patient who
had fever treated versus control [8].
Fever and the immune response
Increased temperature is known to induce changes in many
of the effector cells of the immune response. In addition to
these changes, fever induces the heat shock response. The223
heat shock response is a complex reaction to fever, to
cytokines, or to numerous other stimuli. The end result of this
reaction is production of heat shock proteins (HSPs), a class of
proteins crucial to cellular survival [34]. Ritossa first reported
the heat shock response in 1962 when he noticed changes in
the Drosphilia chromosome in response to increased tempera-
ture [35]. The protein products of these chromosomal changes
were subsequently isolated and called HSPs [36].
The heat shock response provides a cell or organism with ther-
motolerance. When a cell is subjected to a sublethal heat
stress, this sublethal stress protects the organism from a sub-
sequent potentially lethal heat stress [37]. This response
seems to not only function to provide protection from heat, but
can, by a mechanism called cross-tolerance, be induced by a
particular stressor (e.g. heat) and can protect against cell death
from an entirely different lethal stress (e.g. endotoxin) [34].
HSPs have subsequently been found in numerous organisms,
and the DNA sequencing and subsequent protein structure is
highly preserved between organisms [38]. Because they are
so well preserved throughout nature, it is postulated that
HSPs are critical for cell survival. They are molecular chaper-
ones that escort proteins marked for translocation throughout
the organelles of a cell, they participate in refolding proteins
that have become denatured during cellular stress, and they
transport severely damaged proteins to proteolytic organelles
for destruction [39]. Additionally, HSPs also are important in
the apoptotic response, modulating the immune response,
and in regulating steroid hormone receptors.
Inducible HSPs exist in the cytosol, bound to proteins called
heat shock factors (HSFs) [34]. A stress causes HSPs to dis-
sociate from HSFs, and the HSFs are then phosphorylated .
These phosphorylated HSFs form a trimer that enters the
nucleus of the cell and, after further phosphorylation, bind to
the cellular DNA on a sequence called a heat shock element.
The heat shock element is a promoter sequence for the HSP.
Binding of the HSF to the heat shock element causes tran-
scription of HSP mRNA. Translation of the mRNA occurs,
and further HSPs are produced [39].
This system is regulated on several levels. HSPs bind to dis-
sociated HSFs in the cytosol, preventing the formation of
further HSF trimers to act as DNA promoters. Additionally,
there is evidence of post-transcriptional regulation of HSP
production [34]. In vitro experiments show that while HSP
mRNA is increased secondary to a stressor, the amount of
HSPs produced is variable and is dependent on the magni-
tude of the stressor [40].
Heat shock response: clinical implications in
sepsis
The importance of the heat shock response in vivo has been
demonstrated in numerous experiments. Ryan and colleagues
heated rats from 39°C to 42.5°C and then, 24 hours later,
administered a lethal dose of endotoxin to the animals [10].
The mortality in the control group at 48 hours was 71.4%,
while no rats died in the heat-treated group. Villar and col-
leagues showed that, during intra-abdominal sepsis, previous
heat treatment significantly impacted mortality and reduced
organ injury [12]. In this study, rats underwent heat treatment
18 hours before cecal ligation and puncture. Survival at
7 days was noted, and rats were sacrificed at various times
after the cecal ligation and puncture to examine the organ his-
tology. The HSP-72 levels increased in the lungs and the
heart of heat-treated animals shortly after heat treatment.
Animals that underwent cecal ligation and puncture without
previous heat treatment had no detectable expression of
HSP-72 at any time in the course of their illness. The heat-
treated rats had improved mortality, had less organ damage,
and had less evidence of acute lung injury.
Interestingly, severe sepsis may be associated with a dimin-
ished heat shock response. Lymphocytes obtained from a
group of patients with severe sepsis were compared with lym-
phocytes obtained from critically ill postoperative patients and
healthy volunteers [41]. At baseline, all three groups had similar
percentages of lymphocytes expressing HSP-70. When the
lymphocytes were given an endotoxin challenge, however, the
percentage of lymphocytes that expressed HSP-70 was signifi-
cantly less in the septic group. If patients recovered from
severe sepsis, there was an increase in the percentage of their
lymphocytes that produced HSP-70 to endotoxin challenge.
This may suggest that HSPs modulate the septic response.
There is strong evidence that HSPs have anti-inflammatory
roles.  In vitro studies have shown that the heat shock
response reduces levels of TNF-α, IL-1, IL-6, and IL-10 [42].
This effect is not isolated to cell cultures, as it has also been
demonstrated in murine models of sepsis [43,44]. The ability
of the heat shock response to inhibit a wide array of inflam-
matory mediators implies that it must modulate the septic
response at one or more key regulatory steps. Indeed, recent
data has demonstrated that induction of the heat shock
response downregulates the activity of NF-κB.
Heat shock response and NF-κ κB
NF-κB is a nuclear transcription factor that, when activated,
binds to DNA promoter regions that encode for the mRNA of
numerous inflammatory molecules. The effect of this binding
is to enhance the expression of these inflammatory mediators
[45]. NF-κB, therefore, is a potent upstream modulator of the
proinflammatory response. NF-κB is a dimer composed of
two proteins from the ReL family. It is contained in the cytosol
of the cell, bound to an inhibitory protein called I-κB. During
the process of NF-κB activation, I-κB is phosphorylated by a
kinase called IKK [38]. This causes the I-κB to dissociate
from NF-κB, uncovering the nuclear translocation signal on
the NF-κB dimer. Unbound NF-κB is than able to serve its
role as a DNA promoter to enhance the transcription of
mRNA, which codes for the inflammatory molecules.
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NF-κB activity has been reported to correlate with mortality in
septic shock patients. Borher and colleagues followed daily
NF-κB activity obtained from nuclear extracts of peripheral
blood monocytes. They found that survivors of septic shock,
when compared with patients who died, had significantly less
increases in their daily NF-κB activity. In fact, all five patients
who died had a doubling of their baseline NF-κB activity [46].
In a similar study, Paterson and colleagues showed that there
was increased nuclear activity of NF-κB in both monocytes
and neutrophils of septic patients when compared with
healthy controls [47]. The patients who died from sepsis had
increased levels of NF-κB activity in the nucleus of mono-
cytes, as compared with patients who survived sepsis.
The exact mechanism by which hyperthermia, via induction of
the heat shock response, appears to modulate the immune
response to sepsis is thought to be through inhibition of IKK
proteins [45]. As mentioned earlier, IKK has been shown to
be an important regulator of NF-κB activity. This protein phos-
phorylates I-κB and allows the regulatory protein to disassoci-
ate from NF-κB, thus allowing NF-κB to migrate into the
nucleus of the cell [38,45]. Inhibition of IKK will therefore lead
to decreased NF-κB activation and, ultimately, to less down-
stream proinflammatory cytokine gene expression.
After induction of the heat shock response with TNF-α,
human respiratory and alveolar cells had less production of
inflammatory cytokines, had less phosphorylated I-κB, had
higher total levels of I-κB, and had less IKK activity [48]. Addi-
tionally, recent in vitro experiments in human endothelial cells
have duplicated this work, showing that the heat shock
response reduces the activation of IKK, thereby reducing the
phosphorylation of the inhibitory protein I-κB and preventing
activation of NF-κB [49].
These data, which link fever and heat shock response to inhi-
bition of NF-κB, and thus decreased downstream cytokine
production, raise an important question about the wisdom of
treating hypothermia in septic patients.
Summary
Fever in the ICU, and especially in patients with sepsis, is
extremely common. It occurs from activity of endogenous
pyrogens that enhance prostaglandin E2 production in the
pre-optic region of the hypothalamus. Drugs that inhibit
COX-2, as well as measures that promote active cooling, are
effective at suppressing fever and are frequently used during
critically illness. Despite their widespread use, there is data
that suggest fever is beneficial to animals with infection, and
there is no evidence that treating fever changes mortality.
There is theoretical benefit that, through the heat shock
response and subsequent reduction of NF-κB, fever may play
a protective role in the survival of patients with severe sepsis.
In the absence of meaningful evidence for the beneficial
effects of fever reduction, the commonplace reduction of
fever in critically ill patients must be called into question.
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